为评价普罗布考调脂作用，将７２例原发性高脂血症者随机分为２组，每组３６例，Ｐ组服普罗布考（Ｐｒｏｂｕｃｏｌ）１．０ｇ／ｄ；Ｆ组服非诺贝特（Ｆｅｎｏｆｉｂｒａｔｅ）０．３ｇ／ｄ，疗程均为３个月。治疗结束时Ｐ组和Ｆ组服药前后比较，血清总蛋固醇（ＴＣ）降低３７１％和２７３％，低密度脂蛋白胆固醇（ＬＤＬＣ）降低３９４％和３２６％，甘油三酯降低１７５％和４８６％，高密度脂蛋白胆固醇（ＨＤＬＣ）Ｐ组降低２８０％，Ｆ组升高１９７％，Ｆ组降低脂蛋白（ａ）１９３％。结果表明，Ｐ组调脂作用ＴＣ，ＬＤＬＣ优于Ｆ组，ＴＧ及ＨＤＬＣ逊于Ｆ组。两组副反应情况类似，但Ｐ组程度较轻 In order to evaluate the effect of probucol on lipid-lowering, 72 patients with primary hyperlipidemia were randomly divided into two groups, 36 cases in each group, P group received Probucol 1.0g / d, F group Fenofibrate 0.3g / d, treatment are 3 months. At the end of treatment, serum total cholesterol (TC) decreased 371% and 273%, LDLC decreased 394% and 32, respectively 6%, triglycerides decreased by 175% and 486%, HDLC decreased by 280% in P group, 197% in F group, decreased lipoprotein in group F (A) 193%. The results showed that the lipid-lowering effect of P group TC, LDL C better than the F group, TG and HDL C inferior to the F group. The side effects were similar in both groups, but the P group was less severe